nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—TEK—coronary artery disease	0.187	0.497	CbGaD
Vandetanib—KDR—coronary artery disease	0.0913	0.242	CbGaD
Vandetanib—VEGFA—coronary artery disease	0.0774	0.206	CbGaD
Vandetanib—ORM1—Penbutolol—coronary artery disease	0.0324	0.117	CbGbCtD
Vandetanib—ORM1—Pitavastatin—coronary artery disease	0.0283	0.102	CbGbCtD
Vandetanib—ALB—coronary artery disease	0.0208	0.0553	CbGaD
Vandetanib—ABCC1—Rosuvastatin—coronary artery disease	0.019	0.0687	CbGbCtD
Vandetanib—ABCG2—Pitavastatin—coronary artery disease	0.0173	0.0624	CbGbCtD
Vandetanib—ABCG2—Telmisartan—coronary artery disease	0.0173	0.0624	CbGbCtD
Vandetanib—ABCC1—Atorvastatin—coronary artery disease	0.0158	0.0569	CbGbCtD
Vandetanib—ABCG2—Rosuvastatin—coronary artery disease	0.0127	0.046	CbGbCtD
Vandetanib—ABCG2—Ezetimibe—coronary artery disease	0.0127	0.046	CbGbCtD
Vandetanib—ALB—Pitavastatin—coronary artery disease	0.0119	0.043	CbGbCtD
Vandetanib—ABCG2—Pravastatin—coronary artery disease	0.0116	0.0418	CbGbCtD
Vandetanib—ALB—Valsartan—coronary artery disease	0.0116	0.0418	CbGbCtD
Vandetanib—ALB—Rosuvastatin—coronary artery disease	0.00878	0.0317	CbGbCtD
Vandetanib—ALB—Acetylsalicylic acid—coronary artery disease	0.00856	0.0309	CbGbCtD
Vandetanib—ALB—Captopril—coronary artery disease	0.00845	0.0305	CbGbCtD
Vandetanib—CYP3A4—Ticagrelor—coronary artery disease	0.00691	0.025	CbGbCtD
Vandetanib—ALB—Furosemide—coronary artery disease	0.00679	0.0245	CbGbCtD
Vandetanib—ALB—Losartan—coronary artery disease	0.00665	0.024	CbGbCtD
Vandetanib—CYP3A4—Fenofibrate—coronary artery disease	0.00616	0.0222	CbGbCtD
Vandetanib—CYP3A4—Gemfibrozil—coronary artery disease	0.00493	0.0178	CbGbCtD
Vandetanib—CYP3A4—Clopidogrel—coronary artery disease	0.00427	0.0154	CbGbCtD
Vandetanib—CYP3A4—Eplerenone—coronary artery disease	0.00397	0.0143	CbGbCtD
Vandetanib—CYP3A4—Enalapril—coronary artery disease	0.00354	0.0128	CbGbCtD
Vandetanib—CYP3A4—Rosuvastatin—coronary artery disease	0.00275	0.00994	CbGbCtD
Vandetanib—CYP3A4—Ezetimibe—coronary artery disease	0.00275	0.00994	CbGbCtD
Vandetanib—CYP3A4—Simvastatin—coronary artery disease	0.00256	0.00924	CbGbCtD
Vandetanib—CYP3A4—Pravastatin—coronary artery disease	0.0025	0.00904	CbGbCtD
Vandetanib—CYP3A4—Lovastatin—coronary artery disease	0.0025	0.00904	CbGbCtD
Vandetanib—CYP3A4—Atorvastatin—coronary artery disease	0.00228	0.00823	CbGbCtD
Vandetanib—CYP3A4—Losartan—coronary artery disease	0.00209	0.00753	CbGbCtD
Vandetanib—RET—autonomic nervous system—coronary artery disease	0.00197	0.0373	CbGeAlD
Vandetanib—FLT4—endothelium—coronary artery disease	0.00107	0.0203	CbGeAlD
Vandetanib—RIPK2—endothelium—coronary artery disease	0.00107	0.0201	CbGeAlD
Vandetanib—VEGFA—Timolol—Penbutolol—coronary artery disease	0.00103	0.408	CbGdCrCtD
Vandetanib—TEK—artery—coronary artery disease	0.00102	0.0193	CbGeAlD
Vandetanib—SRC—artery—coronary artery disease	0.000906	0.0171	CbGeAlD
Vandetanib—TEK—endothelium—coronary artery disease	0.000862	0.0163	CbGeAlD
Vandetanib—Bosutinib—RPS6KB1—coronary artery disease	0.000857	0.668	CrCbGaD
Vandetanib—KDR—artery—coronary artery disease	0.000834	0.0158	CbGeAlD
Vandetanib—STK35—cardiac ventricle—coronary artery disease	0.000767	0.0145	CbGeAlD
Vandetanib—SRC—endothelium—coronary artery disease	0.000766	0.0145	CbGeAlD
Vandetanib—STK35—myocardium—coronary artery disease	0.000722	0.0136	CbGeAlD
Vandetanib—VEGFA—cardiac ventricle—coronary artery disease	0.000706	0.0133	CbGeAlD
Vandetanib—KDR—endothelium—coronary artery disease	0.000704	0.0133	CbGeAlD
Vandetanib—RIPK2—myocardium—coronary artery disease	0.000666	0.0126	CbGeAlD
Vandetanib—VEGFA—myocardium—coronary artery disease	0.000664	0.0126	CbGeAlD
Vandetanib—MKNK1—cardiac ventricle—coronary artery disease	0.000636	0.012	CbGeAlD
Vandetanib—AXL—cardiac ventricle—coronary artery disease	0.000626	0.0118	CbGeAlD
Vandetanib—BLK—blood—coronary artery disease	0.000615	0.0116	CbGeAlD
Vandetanib—SLK—cardiac ventricle—coronary artery disease	0.000602	0.0114	CbGeAlD
Vandetanib—MKNK1—myocardium—coronary artery disease	0.000598	0.0113	CbGeAlD
Vandetanib—AXL—myocardium—coronary artery disease	0.000588	0.0111	CbGeAlD
Vandetanib—FYN—cardiac ventricle—coronary artery disease	0.000586	0.0111	CbGeAlD
Vandetanib—PTK6—blood—coronary artery disease	0.000583	0.011	CbGeAlD
Vandetanib—TEK—cardiac ventricle—coronary artery disease	0.000572	0.0108	CbGeAlD
Vandetanib—SLK—myocardium—coronary artery disease	0.000566	0.0107	CbGeAlD
Vandetanib—FYN—myocardium—coronary artery disease	0.000551	0.0104	CbGeAlD
Vandetanib—TEK—myocardium—coronary artery disease	0.000538	0.0102	CbGeAlD
Vandetanib—YES1—cardiac ventricle—coronary artery disease	0.000528	0.00999	CbGeAlD
Vandetanib—FLT3—heart—coronary artery disease	0.000514	0.00973	CbGeAlD
Vandetanib—STK35—heart—coronary artery disease	0.000504	0.00953	CbGeAlD
Vandetanib—YES1—myocardium—coronary artery disease	0.000497	0.0094	CbGeAlD
Vandetanib—ABL2—heart—coronary artery disease	0.000491	0.00928	CbGeAlD
Vandetanib—FLT3—cardiovascular system—coronary artery disease	0.000485	0.00918	CbGeAlD
Vandetanib—PLK4—blood—coronary artery disease	0.00048	0.00909	CbGeAlD
Vandetanib—EGFR—heart—coronary artery disease	0.000479	0.00906	CbGeAlD
Vandetanib—VEGFA—Enalapril—Captopril—coronary artery disease	0.000478	0.19	CbGdCrCtD
Vandetanib—KDR—cardiac ventricle—coronary artery disease	0.000468	0.00884	CbGeAlD
Vandetanib—FLT4—heart—coronary artery disease	0.000467	0.00883	CbGeAlD
Vandetanib—RIPK2—heart—coronary artery disease	0.000465	0.00878	CbGeAlD
Vandetanib—VEGFA—heart—coronary artery disease	0.000463	0.00876	CbGeAlD
Vandetanib—IRAK4—heart—coronary artery disease	0.000454	0.00858	CbGeAlD
Vandetanib—LYN—blood—coronary artery disease	0.000449	0.00849	CbGeAlD
Vandetanib—ERBB3—heart—coronary artery disease	0.000445	0.00841	CbGeAlD
Vandetanib—FLT4—cardiovascular system—coronary artery disease	0.000441	0.00833	CbGeAlD
Vandetanib—MAP2K5—myocardium—coronary artery disease	0.00044	0.00832	CbGeAlD
Vandetanib—KDR—myocardium—coronary artery disease	0.00044	0.00832	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—coronary artery disease	0.000438	0.00829	CbGeAlD
Vandetanib—STK35—cardiac atrium—coronary artery disease	0.000431	0.00815	CbGeAlD
Vandetanib—MKNK1—heart—coronary artery disease	0.000417	0.00789	CbGeAlD
Vandetanib—LCK—heart—coronary artery disease	0.000412	0.0078	CbGeAlD
Vandetanib—RET—heart—coronary artery disease	0.000412	0.0078	CbGeAlD
Vandetanib—FGR—heart—coronary artery disease	0.000412	0.0078	CbGeAlD
Vandetanib—AXL—heart—coronary artery disease	0.000411	0.00777	CbGeAlD
Vandetanib—PDGFRB—cardiac ventricle—coronary artery disease	0.000405	0.00765	CbGeAlD
Vandetanib—FMO3—heart—coronary artery disease	0.000398	0.00753	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—coronary artery disease	0.000397	0.00751	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—coronary artery disease	0.000396	0.00749	CbGeAlD
Vandetanib—SLK—heart—coronary artery disease	0.000395	0.00748	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—coronary artery disease	0.000394	0.00745	CbGeAlD
Vandetanib—FGR—cardiovascular system—coronary artery disease	0.000389	0.00736	CbGeAlD
Vandetanib—AXL—cardiovascular system—coronary artery disease	0.000388	0.00733	CbGeAlD
Vandetanib—FYN—heart—coronary artery disease	0.000384	0.00727	CbGeAlD
Vandetanib—FLT3—blood—coronary artery disease	0.000384	0.00726	CbGeAlD
Vandetanib—PDGFRB—myocardium—coronary artery disease	0.000381	0.0072	CbGeAlD
Vandetanib—TEK—heart—coronary artery disease	0.000376	0.0071	CbGeAlD
Vandetanib—MAP4K5—heart—coronary artery disease	0.000376	0.0071	CbGeAlD
Vandetanib—ABL2—blood—coronary artery disease	0.000366	0.00693	CbGeAlD
Vandetanib—FYN—cardiovascular system—coronary artery disease	0.000363	0.00686	CbGeAlD
Vandetanib—ABL1—cardiac ventricle—coronary artery disease	0.000361	0.00682	CbGeAlD
Vandetanib—EPHB6—heart—coronary artery disease	0.000359	0.00679	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—coronary artery disease	0.000357	0.00675	CbGeAlD
Vandetanib—TEK—cardiovascular system—coronary artery disease	0.000354	0.0067	CbGeAlD
Vandetanib—AXL—cardiac atrium—coronary artery disease	0.000351	0.00664	CbGeAlD
Vandetanib—FLT4—blood—coronary artery disease	0.000349	0.00659	CbGeAlD
Vandetanib—YES1—heart—coronary artery disease	0.000347	0.00656	CbGeAlD
Vandetanib—RIPK2—blood—coronary artery disease	0.000347	0.00656	CbGeAlD
Vandetanib—STK10—heart—coronary artery disease	0.000344	0.0065	CbGeAlD
Vandetanib—ABL1—myocardium—coronary artery disease	0.000339	0.00642	CbGeAlD
Vandetanib—IRAK4—blood—coronary artery disease	0.000339	0.0064	CbGeAlD
Vandetanib—SLK—cardiac atrium—coronary artery disease	0.000338	0.00639	CbGeAlD
Vandetanib—SRC—heart—coronary artery disease	0.000334	0.00631	CbGeAlD
Vandetanib—FYN—cardiac atrium—coronary artery disease	0.000329	0.00622	CbGeAlD
Vandetanib—STK10—cardiovascular system—coronary artery disease	0.000324	0.00613	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—coronary artery disease	0.000321	0.00608	CbGeAlD
Vandetanib—TEK—cardiac atrium—coronary artery disease	0.000321	0.00608	CbGeAlD
Vandetanib—SRC—cardiovascular system—coronary artery disease	0.000315	0.00596	CbGeAlD
Vandetanib—MKNK1—blood—coronary artery disease	0.000312	0.00589	CbGeAlD
Vandetanib—FGR—blood—coronary artery disease	0.000308	0.00582	CbGeAlD
Vandetanib—RET—blood—coronary artery disease	0.000308	0.00582	CbGeAlD
Vandetanib—LCK—blood—coronary artery disease	0.000308	0.00582	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—coronary artery disease	0.000307	0.00581	CbGeAlD
Vandetanib—KDR—heart—coronary artery disease	0.000307	0.00581	CbGeAlD
Vandetanib—MAP2K5—heart—coronary artery disease	0.000307	0.00581	CbGeAlD
Vandetanib—YES1—cardiac atrium—coronary artery disease	0.000297	0.00561	CbGeAlD
Vandetanib—SLK—blood—coronary artery disease	0.000295	0.00558	CbGeAlD
Vandetanib—KDR—cardiovascular system—coronary artery disease	0.00029	0.00548	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—coronary artery disease	0.00029	0.00548	CbGeAlD
Vandetanib—FYN—blood—coronary artery disease	0.000287	0.00542	CbGeAlD
Vandetanib—SRC—cardiac atrium—coronary artery disease	0.000285	0.0054	CbGeAlD
Vandetanib—MAP4K5—blood—coronary artery disease	0.00028	0.0053	CbGeAlD
Vandetanib—TEK—blood—coronary artery disease	0.00028	0.0053	CbGeAlD
Vandetanib—EPHB6—blood—coronary artery disease	0.000268	0.00507	CbGeAlD
Vandetanib—PDGFRB—heart—coronary artery disease	0.000266	0.00503	CbGeAlD
Vandetanib—KDR—cardiac atrium—coronary artery disease	0.000263	0.00497	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—coronary artery disease	0.000263	0.00497	CbGeAlD
Vandetanib—YES1—blood—coronary artery disease	0.000259	0.0049	CbGeAlD
Vandetanib—ABCC1—myocardium—coronary artery disease	0.000258	0.00489	CbGeAlD
Vandetanib—VEGFA—Enalapril—Perindopril—coronary artery disease	0.000258	0.103	CbGdCrCtD
Vandetanib—STK10—blood—coronary artery disease	0.000257	0.00485	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—coronary artery disease	0.000251	0.00474	CbGeAlD
Vandetanib—SRC—blood—coronary artery disease	0.000249	0.00471	CbGeAlD
Vandetanib—ERBB3—Alprenolol—Penbutolol—coronary artery disease	0.000241	0.0958	CbGdCrCtD
Vandetanib—ABL1—heart—coronary artery disease	0.000237	0.00448	CbGeAlD
Vandetanib—MAP2K5—blood—coronary artery disease	0.000229	0.00433	CbGeAlD
Vandetanib—KDR—blood—coronary artery disease	0.000229	0.00433	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—coronary artery disease	0.000227	0.0043	CbGeAlD
Vandetanib—ABL1—cardiovascular system—coronary artery disease	0.000223	0.00423	CbGeAlD
Vandetanib—ALB—heart—coronary artery disease	0.000219	0.00413	CbGeAlD
Vandetanib—ABL1—cardiac atrium—coronary artery disease	0.000203	0.00383	CbGeAlD
Vandetanib—VEGFA—Enalapril—Trandolapril—coronary artery disease	0.000201	0.0801	CbGdCrCtD
Vandetanib—PDGFRB—blood—coronary artery disease	0.000198	0.00375	CbGeAlD
Vandetanib—ORM1—blood—coronary artery disease	0.000186	0.00352	CbGeAlD
Vandetanib—ABCC1—heart—coronary artery disease	0.00018	0.00341	CbGeAlD
Vandetanib—ABL1—blood—coronary artery disease	0.000177	0.00334	CbGeAlD
Vandetanib—Gefitinib—CYP2C19—coronary artery disease	0.000175	0.136	CrCbGaD
Vandetanib—VEGFA—Enalapril—Lisinopril—coronary artery disease	0.000158	0.0627	CbGdCrCtD
Vandetanib—Erlotinib—ALB—coronary artery disease	0.000155	0.121	CrCbGaD
Vandetanib—ABCC1—cardiac atrium—coronary artery disease	0.000154	0.00292	CbGeAlD
Vandetanib—VEGFA—Enalapril—Ramipril—coronary artery disease	0.000153	0.0607	CbGdCrCtD
Vandetanib—ABCG2—heart—coronary artery disease	0.000149	0.00282	CbGeAlD
Vandetanib—ABCC1—blood—coronary artery disease	0.000135	0.00255	CbGeAlD
Vandetanib—ABCG2—blood—coronary artery disease	0.000111	0.00211	CbGeAlD
Vandetanib—Gefitinib—ALB—coronary artery disease	9.69e-05	0.0755	CrCbGaD
Vandetanib—CYP3A4—blood—coronary artery disease	7.76e-05	0.00147	CbGeAlD
Vandetanib—Vision blurred—Lisinopril—coronary artery disease	4.34e-05	0.000313	CcSEcCtD
Vandetanib—Paraesthesia—Losartan—coronary artery disease	4.34e-05	0.000313	CcSEcCtD
Vandetanib—Gastrointestinal pain—Captopril—coronary artery disease	4.34e-05	0.000313	CcSEcCtD
Vandetanib—Cough—Timolol—coronary artery disease	4.33e-05	0.000312	CcSEcCtD
Vandetanib—Vomiting—Clopidogrel—coronary artery disease	4.33e-05	0.000312	CcSEcCtD
Vandetanib—Diarrhoea—Simvastatin—coronary artery disease	4.33e-05	0.000312	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Furosemide—coronary artery disease	4.33e-05	0.000312	CcSEcCtD
Vandetanib—Chest pain—Ramipril—coronary artery disease	4.32e-05	0.000312	CcSEcCtD
Vandetanib—Arthralgia—Ramipril—coronary artery disease	4.32e-05	0.000312	CcSEcCtD
Vandetanib—Fatigue—Furosemide—coronary artery disease	4.32e-05	0.000311	CcSEcCtD
Vandetanib—Tremor—Lisinopril—coronary artery disease	4.32e-05	0.000311	CcSEcCtD
Vandetanib—Abdominal pain—Telmisartan—coronary artery disease	4.32e-05	0.000311	CcSEcCtD
Vandetanib—Body temperature increased—Telmisartan—coronary artery disease	4.32e-05	0.000311	CcSEcCtD
Vandetanib—Dyspnoea—Losartan—coronary artery disease	4.31e-05	0.000311	CcSEcCtD
Vandetanib—Anxiety—Ramipril—coronary artery disease	4.31e-05	0.000311	CcSEcCtD
Vandetanib—Vomiting—Lovastatin—coronary artery disease	4.3e-05	0.00031	CcSEcCtD
Vandetanib—Dizziness—Eplerenone—coronary artery disease	4.3e-05	0.00031	CcSEcCtD
Vandetanib—Rash—Clopidogrel—coronary artery disease	4.3e-05	0.00031	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	4.29e-05	0.00031	CcSEcCtD
Vandetanib—Dermatitis—Clopidogrel—coronary artery disease	4.29e-05	0.000309	CcSEcCtD
Vandetanib—Asthenia—Valsartan—coronary artery disease	4.29e-05	0.000309	CcSEcCtD
Vandetanib—Hypertension—Timolol—coronary artery disease	4.29e-05	0.000309	CcSEcCtD
Vandetanib—Constipation—Furosemide—coronary artery disease	4.29e-05	0.000309	CcSEcCtD
Vandetanib—Pain—Furosemide—coronary artery disease	4.29e-05	0.000309	CcSEcCtD
Vandetanib—Asthenia—Olmesartan—coronary artery disease	4.27e-05	0.000308	CcSEcCtD
Vandetanib—Headache—Clopidogrel—coronary artery disease	4.27e-05	0.000308	CcSEcCtD
Vandetanib—Rash—Lovastatin—coronary artery disease	4.27e-05	0.000308	CcSEcCtD
Vandetanib—Dermatitis—Lovastatin—coronary artery disease	4.26e-05	0.000307	CcSEcCtD
Vandetanib—Dyspepsia—Losartan—coronary artery disease	4.26e-05	0.000307	CcSEcCtD
Vandetanib—Headache—Lovastatin—coronary artery disease	4.24e-05	0.000306	CcSEcCtD
Vandetanib—Pruritus—Valsartan—coronary artery disease	4.23e-05	0.000305	CcSEcCtD
Vandetanib—Dry mouth—Ramipril—coronary artery disease	4.23e-05	0.000305	CcSEcCtD
Vandetanib—Chest pain—Timolol—coronary artery disease	4.23e-05	0.000305	CcSEcCtD
Vandetanib—Arthralgia—Timolol—coronary artery disease	4.23e-05	0.000305	CcSEcCtD
Vandetanib—Vomiting—Ezetimibe—coronary artery disease	4.22e-05	0.000304	CcSEcCtD
Vandetanib—Gastrointestinal pain—Perindopril—coronary artery disease	4.21e-05	0.000304	CcSEcCtD
Vandetanib—Anxiety—Timolol—coronary artery disease	4.21e-05	0.000304	CcSEcCtD
Vandetanib—Pruritus—Olmesartan—coronary artery disease	4.21e-05	0.000303	CcSEcCtD
Vandetanib—Decreased appetite—Losartan—coronary artery disease	4.2e-05	0.000303	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	4.2e-05	0.000303	CcSEcCtD
Vandetanib—Abdominal pain—Captopril—coronary artery disease	4.2e-05	0.000303	CcSEcCtD
Vandetanib—Body temperature increased—Captopril—coronary artery disease	4.2e-05	0.000303	CcSEcCtD
Vandetanib—Dizziness—Simvastatin—coronary artery disease	4.19e-05	0.000302	CcSEcCtD
Vandetanib—Rash—Ezetimibe—coronary artery disease	4.19e-05	0.000302	CcSEcCtD
Vandetanib—Dermatitis—Ezetimibe—coronary artery disease	4.18e-05	0.000301	CcSEcCtD
Vandetanib—Asthenia—Niacin—coronary artery disease	4.17e-05	0.000301	CcSEcCtD
Vandetanib—Fatigue—Losartan—coronary artery disease	4.17e-05	0.000301	CcSEcCtD
Vandetanib—Headache—Ezetimibe—coronary artery disease	4.16e-05	0.0003	CcSEcCtD
Vandetanib—Oedema—Ramipril—coronary artery disease	4.15e-05	0.000299	CcSEcCtD
Vandetanib—Dry mouth—Timolol—coronary artery disease	4.13e-05	0.000298	CcSEcCtD
Vandetanib—Constipation—Losartan—coronary artery disease	4.13e-05	0.000298	CcSEcCtD
Vandetanib—Pain—Losartan—coronary artery disease	4.13e-05	0.000298	CcSEcCtD
Vandetanib—Vomiting—Eplerenone—coronary artery disease	4.13e-05	0.000298	CcSEcCtD
Vandetanib—Nausea—Fenofibrate—coronary artery disease	4.12e-05	0.000297	CcSEcCtD
Vandetanib—Pruritus—Niacin—coronary artery disease	4.11e-05	0.000296	CcSEcCtD
Vandetanib—Asthenia—Pravastatin—coronary artery disease	4.11e-05	0.000296	CcSEcCtD
Vandetanib—Gastrointestinal pain—Furosemide—coronary artery disease	4.1e-05	0.000295	CcSEcCtD
Vandetanib—Rash—Eplerenone—coronary artery disease	4.1e-05	0.000295	CcSEcCtD
Vandetanib—Dermatitis—Eplerenone—coronary artery disease	4.09e-05	0.000295	CcSEcCtD
Vandetanib—Diarrhoea—Valsartan—coronary artery disease	4.09e-05	0.000295	CcSEcCtD
Vandetanib—Abdominal pain—Perindopril—coronary artery disease	4.07e-05	0.000294	CcSEcCtD
Vandetanib—Body temperature increased—Perindopril—coronary artery disease	4.07e-05	0.000294	CcSEcCtD
Vandetanib—Diarrhoea—Olmesartan—coronary artery disease	4.07e-05	0.000293	CcSEcCtD
Vandetanib—Headache—Eplerenone—coronary artery disease	4.07e-05	0.000293	CcSEcCtD
Vandetanib—Nervous system disorder—Ramipril—coronary artery disease	4.07e-05	0.000293	CcSEcCtD
Vandetanib—Thrombocytopenia—Ramipril—coronary artery disease	4.06e-05	0.000293	CcSEcCtD
Vandetanib—Oedema—Timolol—coronary artery disease	4.05e-05	0.000292	CcSEcCtD
Vandetanib—Pruritus—Pravastatin—coronary artery disease	4.05e-05	0.000292	CcSEcCtD
Vandetanib—Loss of consciousness—Lisinopril—coronary artery disease	4.05e-05	0.000292	CcSEcCtD
Vandetanib—Nausea—Clopidogrel—coronary artery disease	4.05e-05	0.000292	CcSEcCtD
Vandetanib—Skin disorder—Ramipril—coronary artery disease	4.03e-05	0.00029	CcSEcCtD
Vandetanib—Infection—Timolol—coronary artery disease	4.03e-05	0.00029	CcSEcCtD
Vandetanib—Vomiting—Simvastatin—coronary artery disease	4.02e-05	0.00029	CcSEcCtD
Vandetanib—Cough—Lisinopril—coronary artery disease	4.02e-05	0.00029	CcSEcCtD
Vandetanib—Nausea—Lovastatin—coronary artery disease	4.02e-05	0.00029	CcSEcCtD
Vandetanib—Rash—Simvastatin—coronary artery disease	3.99e-05	0.000288	CcSEcCtD
Vandetanib—Dermatitis—Simvastatin—coronary artery disease	3.99e-05	0.000287	CcSEcCtD
Vandetanib—Asthenia—Trandolapril—coronary artery disease	3.99e-05	0.000287	CcSEcCtD
Vandetanib—Diarrhoea—Niacin—coronary artery disease	3.98e-05	0.000287	CcSEcCtD
Vandetanib—Nervous system disorder—Timolol—coronary artery disease	3.97e-05	0.000287	CcSEcCtD
Vandetanib—Asthenia—Enalapril—coronary artery disease	3.97e-05	0.000286	CcSEcCtD
Vandetanib—Headache—Simvastatin—coronary artery disease	3.97e-05	0.000286	CcSEcCtD
Vandetanib—Abdominal pain—Furosemide—coronary artery disease	3.96e-05	0.000286	CcSEcCtD
Vandetanib—Body temperature increased—Furosemide—coronary artery disease	3.96e-05	0.000286	CcSEcCtD
Vandetanib—Gastrointestinal pain—Losartan—coronary artery disease	3.95e-05	0.000285	CcSEcCtD
Vandetanib—Dizziness—Valsartan—coronary artery disease	3.95e-05	0.000285	CcSEcCtD
Vandetanib—Nausea—Ezetimibe—coronary artery disease	3.94e-05	0.000284	CcSEcCtD
Vandetanib—Skin disorder—Timolol—coronary artery disease	3.94e-05	0.000284	CcSEcCtD
Vandetanib—Dizziness—Olmesartan—coronary artery disease	3.93e-05	0.000284	CcSEcCtD
Vandetanib—Pruritus—Trandolapril—coronary artery disease	3.93e-05	0.000283	CcSEcCtD
Vandetanib—Chest pain—Lisinopril—coronary artery disease	3.92e-05	0.000283	CcSEcCtD
Vandetanib—Arthralgia—Lisinopril—coronary artery disease	3.92e-05	0.000283	CcSEcCtD
Vandetanib—Asthenia—Telmisartan—coronary artery disease	3.92e-05	0.000282	CcSEcCtD
Vandetanib—Pruritus—Enalapril—coronary artery disease	3.92e-05	0.000282	CcSEcCtD
Vandetanib—Diarrhoea—Pravastatin—coronary artery disease	3.92e-05	0.000282	CcSEcCtD
Vandetanib—Anxiety—Lisinopril—coronary artery disease	3.91e-05	0.000282	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	3.89e-05	0.000281	CcSEcCtD
Vandetanib—Pruritus—Telmisartan—coronary artery disease	3.86e-05	0.000278	CcSEcCtD
Vandetanib—Nausea—Eplerenone—coronary artery disease	3.86e-05	0.000278	CcSEcCtD
Vandetanib—Dizziness—Niacin—coronary artery disease	3.84e-05	0.000277	CcSEcCtD
Vandetanib—Dry mouth—Lisinopril—coronary artery disease	3.84e-05	0.000277	CcSEcCtD
Vandetanib—Abdominal pain—Losartan—coronary artery disease	3.82e-05	0.000276	CcSEcCtD
Vandetanib—Body temperature increased—Losartan—coronary artery disease	3.82e-05	0.000276	CcSEcCtD
Vandetanib—Asthenia—Captopril—coronary artery disease	3.81e-05	0.000275	CcSEcCtD
Vandetanib—Diarrhoea—Trandolapril—coronary artery disease	3.8e-05	0.000274	CcSEcCtD
Vandetanib—Vomiting—Valsartan—coronary artery disease	3.8e-05	0.000274	CcSEcCtD
Vandetanib—Diarrhoea—Enalapril—coronary artery disease	3.79e-05	0.000273	CcSEcCtD
Vandetanib—Dizziness—Pravastatin—coronary artery disease	3.78e-05	0.000273	CcSEcCtD
Vandetanib—Vomiting—Olmesartan—coronary artery disease	3.78e-05	0.000273	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Ramipril—coronary artery disease	3.78e-05	0.000272	CcSEcCtD
Vandetanib—Rash—Valsartan—coronary artery disease	3.77e-05	0.000272	CcSEcCtD
Vandetanib—Dermatitis—Valsartan—coronary artery disease	3.77e-05	0.000271	CcSEcCtD
Vandetanib—Nausea—Simvastatin—coronary artery disease	3.76e-05	0.000271	CcSEcCtD
Vandetanib—Oedema—Lisinopril—coronary artery disease	3.76e-05	0.000271	CcSEcCtD
Vandetanib—Pruritus—Captopril—coronary artery disease	3.76e-05	0.000271	CcSEcCtD
Vandetanib—Rash—Olmesartan—coronary artery disease	3.75e-05	0.00027	CcSEcCtD
Vandetanib—Insomnia—Ramipril—coronary artery disease	3.75e-05	0.00027	CcSEcCtD
Vandetanib—Dermatitis—Olmesartan—coronary artery disease	3.75e-05	0.00027	CcSEcCtD
Vandetanib—Headache—Valsartan—coronary artery disease	3.74e-05	0.00027	CcSEcCtD
Vandetanib—Diarrhoea—Telmisartan—coronary artery disease	3.74e-05	0.000269	CcSEcCtD
Vandetanib—Infection—Lisinopril—coronary artery disease	3.74e-05	0.000269	CcSEcCtD
Vandetanib—Headache—Olmesartan—coronary artery disease	3.73e-05	0.000269	CcSEcCtD
Vandetanib—Paraesthesia—Ramipril—coronary artery disease	3.72e-05	0.000268	CcSEcCtD
Vandetanib—Asthenia—Perindopril—coronary artery disease	3.7e-05	0.000267	CcSEcCtD
Vandetanib—Dyspnoea—Ramipril—coronary artery disease	3.7e-05	0.000266	CcSEcCtD
Vandetanib—Vomiting—Niacin—coronary artery disease	3.7e-05	0.000266	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Timolol—coronary artery disease	3.69e-05	0.000266	CcSEcCtD
Vandetanib—Thrombocytopenia—Lisinopril—coronary artery disease	3.68e-05	0.000265	CcSEcCtD
Vandetanib—Dizziness—Trandolapril—coronary artery disease	3.68e-05	0.000265	CcSEcCtD
Vandetanib—Insomnia—Timolol—coronary artery disease	3.67e-05	0.000264	CcSEcCtD
Vandetanib—Rash—Niacin—coronary artery disease	3.66e-05	0.000264	CcSEcCtD
Vandetanib—Dermatitis—Niacin—coronary artery disease	3.66e-05	0.000264	CcSEcCtD
Vandetanib—Dizziness—Enalapril—coronary artery disease	3.66e-05	0.000264	CcSEcCtD
Vandetanib—Skin disorder—Lisinopril—coronary artery disease	3.65e-05	0.000263	CcSEcCtD
Vandetanib—Dyspepsia—Ramipril—coronary artery disease	3.65e-05	0.000263	CcSEcCtD
Vandetanib—Pruritus—Perindopril—coronary artery disease	3.65e-05	0.000263	CcSEcCtD
Vandetanib—Headache—Niacin—coronary artery disease	3.64e-05	0.000263	CcSEcCtD
Vandetanib—Paraesthesia—Timolol—coronary artery disease	3.64e-05	0.000262	CcSEcCtD
Vandetanib—Vomiting—Pravastatin—coronary artery disease	3.64e-05	0.000262	CcSEcCtD
Vandetanib—Diarrhoea—Captopril—coronary artery disease	3.63e-05	0.000262	CcSEcCtD
Vandetanib—Dyspnoea—Timolol—coronary artery disease	3.61e-05	0.00026	CcSEcCtD
Vandetanib—Dizziness—Telmisartan—coronary artery disease	3.61e-05	0.00026	CcSEcCtD
Vandetanib—Rash—Pravastatin—coronary artery disease	3.61e-05	0.00026	CcSEcCtD
Vandetanib—Dermatitis—Pravastatin—coronary artery disease	3.61e-05	0.00026	CcSEcCtD
Vandetanib—Decreased appetite—Ramipril—coronary artery disease	3.6e-05	0.00026	CcSEcCtD
Vandetanib—Asthenia—Furosemide—coronary artery disease	3.6e-05	0.000259	CcSEcCtD
Vandetanib—Headache—Pravastatin—coronary artery disease	3.59e-05	0.000258	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Ramipril—coronary artery disease	3.58e-05	0.000258	CcSEcCtD
Vandetanib—Fatigue—Ramipril—coronary artery disease	3.57e-05	0.000258	CcSEcCtD
Vandetanib—Dyspepsia—Timolol—coronary artery disease	3.57e-05	0.000257	CcSEcCtD
Vandetanib—Nausea—Valsartan—coronary artery disease	3.55e-05	0.000256	CcSEcCtD
Vandetanib—Pruritus—Furosemide—coronary artery disease	3.55e-05	0.000256	CcSEcCtD
Vandetanib—Constipation—Ramipril—coronary artery disease	3.55e-05	0.000256	CcSEcCtD
Vandetanib—Nausea—Olmesartan—coronary artery disease	3.53e-05	0.000255	CcSEcCtD
Vandetanib—Vomiting—Trandolapril—coronary artery disease	3.53e-05	0.000255	CcSEcCtD
Vandetanib—Diarrhoea—Perindopril—coronary artery disease	3.53e-05	0.000254	CcSEcCtD
Vandetanib—Decreased appetite—Timolol—coronary artery disease	3.52e-05	0.000254	CcSEcCtD
Vandetanib—Vomiting—Enalapril—coronary artery disease	3.52e-05	0.000254	CcSEcCtD
Vandetanib—Dizziness—Captopril—coronary artery disease	3.51e-05	0.000253	CcSEcCtD
Vandetanib—Rash—Trandolapril—coronary artery disease	3.5e-05	0.000253	CcSEcCtD
Vandetanib—Dermatitis—Trandolapril—coronary artery disease	3.5e-05	0.000252	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Timolol—coronary artery disease	3.5e-05	0.000252	CcSEcCtD
Vandetanib—Fatigue—Timolol—coronary artery disease	3.49e-05	0.000252	CcSEcCtD
Vandetanib—Rash—Enalapril—coronary artery disease	3.49e-05	0.000252	CcSEcCtD
Vandetanib—Dermatitis—Enalapril—coronary artery disease	3.49e-05	0.000251	CcSEcCtD
Vandetanib—Headache—Trandolapril—coronary artery disease	3.48e-05	0.000251	CcSEcCtD
Vandetanib—Vomiting—Telmisartan—coronary artery disease	3.47e-05	0.00025	CcSEcCtD
Vandetanib—Asthenia—Losartan—coronary artery disease	3.47e-05	0.00025	CcSEcCtD
Vandetanib—Headache—Enalapril—coronary artery disease	3.47e-05	0.00025	CcSEcCtD
Vandetanib—Pain—Timolol—coronary artery disease	3.47e-05	0.00025	CcSEcCtD
Vandetanib—Nausea—Niacin—coronary artery disease	3.45e-05	0.000249	CcSEcCtD
Vandetanib—Rash—Telmisartan—coronary artery disease	3.44e-05	0.000248	CcSEcCtD
Vandetanib—Dermatitis—Telmisartan—coronary artery disease	3.44e-05	0.000248	CcSEcCtD
Vandetanib—Diarrhoea—Furosemide—coronary artery disease	3.43e-05	0.000247	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	3.43e-05	0.000247	CcSEcCtD
Vandetanib—Pruritus—Losartan—coronary artery disease	3.42e-05	0.000247	CcSEcCtD
Vandetanib—Headache—Telmisartan—coronary artery disease	3.42e-05	0.000247	CcSEcCtD
Vandetanib—Dizziness—Perindopril—coronary artery disease	3.41e-05	0.000246	CcSEcCtD
Vandetanib—Insomnia—Lisinopril—coronary artery disease	3.4e-05	0.000245	CcSEcCtD
Vandetanib—Nausea—Pravastatin—coronary artery disease	3.4e-05	0.000245	CcSEcCtD
Vandetanib—Gastrointestinal pain—Ramipril—coronary artery disease	3.39e-05	0.000244	CcSEcCtD
Vandetanib—Paraesthesia—Lisinopril—coronary artery disease	3.38e-05	0.000243	CcSEcCtD
Vandetanib—Vomiting—Captopril—coronary artery disease	3.38e-05	0.000243	CcSEcCtD
Vandetanib—Dyspnoea—Lisinopril—coronary artery disease	3.35e-05	0.000242	CcSEcCtD
Vandetanib—Rash—Captopril—coronary artery disease	3.35e-05	0.000241	CcSEcCtD
Vandetanib—Dermatitis—Captopril—coronary artery disease	3.34e-05	0.000241	CcSEcCtD
Vandetanib—Headache—Captopril—coronary artery disease	3.33e-05	0.00024	CcSEcCtD
Vandetanib—Gastrointestinal pain—Timolol—coronary artery disease	3.31e-05	0.000239	CcSEcCtD
Vandetanib—Dizziness—Furosemide—coronary artery disease	3.31e-05	0.000239	CcSEcCtD
Vandetanib—Dyspepsia—Lisinopril—coronary artery disease	3.31e-05	0.000239	CcSEcCtD
Vandetanib—Diarrhoea—Losartan—coronary artery disease	3.31e-05	0.000238	CcSEcCtD
Vandetanib—Nausea—Trandolapril—coronary artery disease	3.3e-05	0.000238	CcSEcCtD
Vandetanib—Nausea—Enalapril—coronary artery disease	3.29e-05	0.000237	CcSEcCtD
Vandetanib—Vomiting—Perindopril—coronary artery disease	3.28e-05	0.000236	CcSEcCtD
Vandetanib—Abdominal pain—Ramipril—coronary artery disease	3.28e-05	0.000236	CcSEcCtD
Vandetanib—Body temperature increased—Ramipril—coronary artery disease	3.28e-05	0.000236	CcSEcCtD
Vandetanib—Decreased appetite—Lisinopril—coronary artery disease	3.27e-05	0.000236	CcSEcCtD
Vandetanib—Rash—Perindopril—coronary artery disease	3.25e-05	0.000234	CcSEcCtD
Vandetanib—Dermatitis—Perindopril—coronary artery disease	3.25e-05	0.000234	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Lisinopril—coronary artery disease	3.25e-05	0.000234	CcSEcCtD
Vandetanib—Nausea—Telmisartan—coronary artery disease	3.24e-05	0.000234	CcSEcCtD
Vandetanib—Fatigue—Lisinopril—coronary artery disease	3.24e-05	0.000234	CcSEcCtD
Vandetanib—Headache—Perindopril—coronary artery disease	3.23e-05	0.000233	CcSEcCtD
Vandetanib—Pain—Lisinopril—coronary artery disease	3.22e-05	0.000232	CcSEcCtD
Vandetanib—Constipation—Lisinopril—coronary artery disease	3.22e-05	0.000232	CcSEcCtD
Vandetanib—Abdominal pain—Timolol—coronary artery disease	3.2e-05	0.000231	CcSEcCtD
Vandetanib—Body temperature increased—Timolol—coronary artery disease	3.2e-05	0.000231	CcSEcCtD
Vandetanib—Dizziness—Losartan—coronary artery disease	3.2e-05	0.00023	CcSEcCtD
Vandetanib—Vomiting—Furosemide—coronary artery disease	3.19e-05	0.00023	CcSEcCtD
Vandetanib—Rash—Furosemide—coronary artery disease	3.16e-05	0.000228	CcSEcCtD
Vandetanib—Dermatitis—Furosemide—coronary artery disease	3.16e-05	0.000228	CcSEcCtD
Vandetanib—Nausea—Captopril—coronary artery disease	3.15e-05	0.000227	CcSEcCtD
Vandetanib—Headache—Furosemide—coronary artery disease	3.14e-05	0.000226	CcSEcCtD
Vandetanib—Gastrointestinal pain—Lisinopril—coronary artery disease	3.07e-05	0.000222	CcSEcCtD
Vandetanib—Vomiting—Losartan—coronary artery disease	3.07e-05	0.000222	CcSEcCtD
Vandetanib—Nausea—Perindopril—coronary artery disease	3.06e-05	0.000221	CcSEcCtD
Vandetanib—Rash—Losartan—coronary artery disease	3.05e-05	0.00022	CcSEcCtD
Vandetanib—Dermatitis—Losartan—coronary artery disease	3.05e-05	0.00022	CcSEcCtD
Vandetanib—Headache—Losartan—coronary artery disease	3.03e-05	0.000218	CcSEcCtD
Vandetanib—Nausea—Furosemide—coronary artery disease	2.98e-05	0.000215	CcSEcCtD
Vandetanib—Asthenia—Ramipril—coronary artery disease	2.97e-05	0.000214	CcSEcCtD
Vandetanib—Body temperature increased—Lisinopril—coronary artery disease	2.97e-05	0.000214	CcSEcCtD
Vandetanib—Abdominal pain—Lisinopril—coronary artery disease	2.97e-05	0.000214	CcSEcCtD
Vandetanib—Pruritus—Ramipril—coronary artery disease	2.93e-05	0.000211	CcSEcCtD
Vandetanib—Asthenia—Timolol—coronary artery disease	2.91e-05	0.00021	CcSEcCtD
Vandetanib—Nausea—Losartan—coronary artery disease	2.87e-05	0.000207	CcSEcCtD
Vandetanib—Pruritus—Timolol—coronary artery disease	2.87e-05	0.000207	CcSEcCtD
Vandetanib—Diarrhoea—Ramipril—coronary artery disease	2.84e-05	0.000204	CcSEcCtD
Vandetanib—Diarrhoea—Timolol—coronary artery disease	2.77e-05	0.0002	CcSEcCtD
Vandetanib—Dizziness—Ramipril—coronary artery disease	2.74e-05	0.000198	CcSEcCtD
Vandetanib—Asthenia—Lisinopril—coronary artery disease	2.7e-05	0.000194	CcSEcCtD
Vandetanib—Dizziness—Timolol—coronary artery disease	2.68e-05	0.000193	CcSEcCtD
Vandetanib—Pruritus—Lisinopril—coronary artery disease	2.66e-05	0.000192	CcSEcCtD
Vandetanib—Vomiting—Ramipril—coronary artery disease	2.64e-05	0.00019	CcSEcCtD
Vandetanib—Rash—Ramipril—coronary artery disease	2.61e-05	0.000188	CcSEcCtD
Vandetanib—Dermatitis—Ramipril—coronary artery disease	2.61e-05	0.000188	CcSEcCtD
Vandetanib—Headache—Ramipril—coronary artery disease	2.6e-05	0.000187	CcSEcCtD
Vandetanib—Vomiting—Timolol—coronary artery disease	2.58e-05	0.000186	CcSEcCtD
Vandetanib—Diarrhoea—Lisinopril—coronary artery disease	2.57e-05	0.000185	CcSEcCtD
Vandetanib—Rash—Timolol—coronary artery disease	2.56e-05	0.000184	CcSEcCtD
Vandetanib—Dermatitis—Timolol—coronary artery disease	2.55e-05	0.000184	CcSEcCtD
Vandetanib—Headache—Timolol—coronary artery disease	2.54e-05	0.000183	CcSEcCtD
Vandetanib—Dizziness—Lisinopril—coronary artery disease	2.49e-05	0.000179	CcSEcCtD
Vandetanib—Nausea—Ramipril—coronary artery disease	2.46e-05	0.000178	CcSEcCtD
Vandetanib—Nausea—Timolol—coronary artery disease	2.41e-05	0.000174	CcSEcCtD
Vandetanib—Vomiting—Lisinopril—coronary artery disease	2.39e-05	0.000172	CcSEcCtD
Vandetanib—Rash—Lisinopril—coronary artery disease	2.37e-05	0.000171	CcSEcCtD
Vandetanib—Dermatitis—Lisinopril—coronary artery disease	2.37e-05	0.000171	CcSEcCtD
Vandetanib—Headache—Lisinopril—coronary artery disease	2.36e-05	0.00017	CcSEcCtD
Vandetanib—Nausea—Lisinopril—coronary artery disease	2.23e-05	0.000161	CcSEcCtD
Vandetanib—FYN—Signaling Pathways—JAK2—coronary artery disease	5.28e-07	3.49e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—coronary artery disease	5.27e-07	3.49e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—coronary artery disease	5.27e-07	3.48e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—coronary artery disease	5.26e-07	3.48e-06	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—coronary artery disease	5.26e-07	3.48e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6R—coronary artery disease	5.25e-07	3.47e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—coronary artery disease	5.24e-07	3.47e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—coronary artery disease	5.24e-07	3.46e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KDR—coronary artery disease	5.23e-07	3.46e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—coronary artery disease	5.23e-07	3.46e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GSK3B—coronary artery disease	5.23e-07	3.46e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MAPK1—coronary artery disease	5.22e-07	3.45e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK14—coronary artery disease	5.2e-07	3.44e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—POMC—coronary artery disease	5.18e-07	3.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CREB1—coronary artery disease	5.18e-07	3.43e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—coronary artery disease	5.17e-07	3.42e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MAPK1—coronary artery disease	5.17e-07	3.42e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—MAPK1—coronary artery disease	5.15e-07	3.41e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LPL—coronary artery disease	5.15e-07	3.4e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—coronary artery disease	5.13e-07	3.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ESR1—coronary artery disease	5.1e-07	3.37e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—coronary artery disease	5.07e-07	3.35e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—coronary artery disease	5.06e-07	3.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6R—coronary artery disease	5.06e-07	3.34e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—F2—coronary artery disease	5.04e-07	3.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FN1—coronary artery disease	5.04e-07	3.33e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—MAPK1—coronary artery disease	5.03e-07	3.33e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—coronary artery disease	5.02e-07	3.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6ST—coronary artery disease	5.02e-07	3.32e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—coronary artery disease	5e-07	3.3e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—coronary artery disease	4.99e-07	3.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—VCAN—coronary artery disease	4.99e-07	3.3e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKBIA—coronary artery disease	4.98e-07	3.29e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK1—coronary artery disease	4.97e-07	3.28e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALDOA—coronary artery disease	4.95e-07	3.27e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—coronary artery disease	4.92e-07	3.25e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—coronary artery disease	4.91e-07	3.25e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—coronary artery disease	4.9e-07	3.24e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—coronary artery disease	4.89e-07	3.24e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—coronary artery disease	4.89e-07	3.23e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CD36—coronary artery disease	4.89e-07	3.23e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—coronary artery disease	4.89e-07	3.23e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPP2CA—coronary artery disease	4.83e-07	3.19e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—coronary artery disease	4.82e-07	3.19e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—coronary artery disease	4.82e-07	3.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DCN—coronary artery disease	4.8e-07	3.18e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—coronary artery disease	4.8e-07	3.17e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK1—coronary artery disease	4.8e-07	3.17e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—coronary artery disease	4.79e-07	3.17e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—coronary artery disease	4.79e-07	3.17e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—coronary artery disease	4.78e-07	3.16e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—coronary artery disease	4.78e-07	3.16e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—coronary artery disease	4.76e-07	3.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGF2—coronary artery disease	4.76e-07	3.15e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—coronary artery disease	4.74e-07	3.14e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—coronary artery disease	4.74e-07	3.13e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—coronary artery disease	4.73e-07	3.13e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK1—coronary artery disease	4.71e-07	3.11e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—coronary artery disease	4.7e-07	3.11e-06	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—coronary artery disease	4.69e-07	3.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—coronary artery disease	4.69e-07	3.1e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—coronary artery disease	4.68e-07	3.1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALDH2—coronary artery disease	4.67e-07	3.09e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—coronary artery disease	4.66e-07	3.08e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—coronary artery disease	4.63e-07	3.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GSK3B—coronary artery disease	4.63e-07	3.06e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—coronary artery disease	4.61e-07	3.05e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MAPK1—coronary artery disease	4.61e-07	3.05e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—POMC—coronary artery disease	4.59e-07	3.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CREB1—coronary artery disease	4.59e-07	3.03e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGF2—coronary artery disease	4.58e-07	3.03e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JAK2—coronary artery disease	4.56e-07	3.02e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—coronary artery disease	4.56e-07	3.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LIPC—coronary artery disease	4.55e-07	3.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	4.55e-07	3.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	4.55e-07	3.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HBA1—coronary artery disease	4.55e-07	3.01e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK1—coronary artery disease	4.53e-07	3e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—coronary artery disease	4.53e-07	2.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOC3—coronary artery disease	4.52e-07	2.99e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—coronary artery disease	4.52e-07	2.99e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—coronary artery disease	4.52e-07	2.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LDLR—coronary artery disease	4.5e-07	2.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—coronary artery disease	4.49e-07	2.97e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—coronary artery disease	4.49e-07	2.97e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—coronary artery disease	4.49e-07	2.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6R—coronary artery disease	4.48e-07	2.96e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—coronary artery disease	4.47e-07	2.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTT1—coronary artery disease	4.44e-07	2.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	4.44e-07	2.94e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—coronary artery disease	4.43e-07	2.93e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—coronary artery disease	4.43e-07	2.93e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—coronary artery disease	4.41e-07	2.92e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—coronary artery disease	4.4e-07	2.91e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—coronary artery disease	4.39e-07	2.91e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JAK2—coronary artery disease	4.39e-07	2.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCLC—coronary artery disease	4.39e-07	2.9e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CETP—coronary artery disease	4.39e-07	2.9e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—coronary artery disease	4.36e-07	2.89e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—coronary artery disease	4.36e-07	2.88e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—coronary artery disease	4.36e-07	2.88e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK1—coronary artery disease	4.34e-07	2.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SDC1—coronary artery disease	4.34e-07	2.87e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—coronary artery disease	4.34e-07	2.87e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—coronary artery disease	4.31e-07	2.85e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—coronary artery disease	4.31e-07	2.85e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—coronary artery disease	4.27e-07	2.82e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—coronary artery disease	4.26e-07	2.82e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—coronary artery disease	4.25e-07	2.81e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—coronary artery disease	4.24e-07	2.81e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—coronary artery disease	4.23e-07	2.8e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—coronary artery disease	4.2e-07	2.78e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—coronary artery disease	4.19e-07	2.77e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK1—coronary artery disease	4.19e-07	2.77e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—coronary artery disease	4.18e-07	2.77e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—coronary artery disease	4.16e-07	2.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—coronary artery disease	4.16e-07	2.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSMB5—coronary artery disease	4.1e-07	2.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSMA6—coronary artery disease	4.1e-07	2.71e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	4.08e-07	2.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—coronary artery disease	4.08e-07	2.7e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—coronary artery disease	4.06e-07	2.68e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF2—coronary artery disease	4.06e-07	2.68e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—coronary artery disease	4.02e-07	2.66e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK1—coronary artery disease	4.01e-07	2.65e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—coronary artery disease	4.01e-07	2.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—coronary artery disease	4.01e-07	2.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CTGF—coronary artery disease	4.01e-07	2.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—coronary artery disease	4.01e-07	2.65e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—coronary artery disease	4e-07	2.65e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—coronary artery disease	4e-07	2.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—coronary artery disease	3.98e-07	2.63e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—coronary artery disease	3.97e-07	2.63e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMGCR—coronary artery disease	3.97e-07	2.63e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT2—coronary artery disease	3.97e-07	2.63e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—coronary artery disease	3.96e-07	2.62e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—coronary artery disease	3.93e-07	2.6e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—coronary artery disease	3.92e-07	2.59e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—coronary artery disease	3.92e-07	2.59e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—coronary artery disease	3.91e-07	2.59e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—coronary artery disease	3.9e-07	2.58e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JAK2—coronary artery disease	3.89e-07	2.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—coronary artery disease	3.88e-07	2.56e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—coronary artery disease	3.87e-07	2.56e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—coronary artery disease	3.86e-07	2.56e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—coronary artery disease	3.86e-07	2.55e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—coronary artery disease	3.84e-07	2.54e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—coronary artery disease	3.82e-07	2.52e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—coronary artery disease	3.78e-07	2.5e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—coronary artery disease	3.77e-07	2.49e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—coronary artery disease	3.76e-07	2.49e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—coronary artery disease	3.76e-07	2.48e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—coronary artery disease	3.74e-07	2.47e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—coronary artery disease	3.72e-07	2.46e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK1—coronary artery disease	3.71e-07	2.45e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—coronary artery disease	3.71e-07	2.45e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—coronary artery disease	3.7e-07	2.45e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—coronary artery disease	3.69e-07	2.44e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—coronary artery disease	3.66e-07	2.42e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK1—coronary artery disease	3.65e-07	2.42e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLCB1—coronary artery disease	3.65e-07	2.42e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—coronary artery disease	3.65e-07	2.41e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—coronary artery disease	3.65e-07	2.41e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—coronary artery disease	3.63e-07	2.4e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—coronary artery disease	3.63e-07	2.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—coronary artery disease	3.62e-07	2.39e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—coronary artery disease	3.59e-07	2.37e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK1—coronary artery disease	3.58e-07	2.37e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—coronary artery disease	3.56e-07	2.36e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—coronary artery disease	3.55e-07	2.35e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—coronary artery disease	3.54e-07	2.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCA1—coronary artery disease	3.54e-07	2.34e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK1—coronary artery disease	3.52e-07	2.33e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—coronary artery disease	3.52e-07	2.33e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—coronary artery disease	3.48e-07	2.3e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—coronary artery disease	3.48e-07	2.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT1—coronary artery disease	3.43e-07	2.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GGT1—coronary artery disease	3.43e-07	2.27e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—coronary artery disease	3.4e-07	2.25e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—coronary artery disease	3.4e-07	2.25e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—coronary artery disease	3.38e-07	2.24e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—coronary artery disease	3.35e-07	2.21e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—coronary artery disease	3.34e-07	2.21e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—coronary artery disease	3.34e-07	2.21e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—coronary artery disease	3.31e-07	2.19e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—coronary artery disease	3.27e-07	2.16e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—coronary artery disease	3.26e-07	2.15e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—coronary artery disease	3.23e-07	2.14e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—coronary artery disease	3.22e-07	2.13e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—coronary artery disease	3.22e-07	2.13e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—coronary artery disease	3.21e-07	2.13e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—coronary artery disease	3.21e-07	2.12e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—coronary artery disease	3.17e-07	2.1e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—coronary artery disease	3.1e-07	2.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—coronary artery disease	3.1e-07	2.05e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—coronary artery disease	3.08e-07	2.04e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—coronary artery disease	3.08e-07	2.04e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—coronary artery disease	3.08e-07	2.04e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—coronary artery disease	3.06e-07	2.02e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	3.05e-07	2.02e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK1—coronary artery disease	3.04e-07	2.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—coronary artery disease	3.04e-07	2.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAT—coronary artery disease	3e-07	1.98e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—coronary artery disease	2.99e-07	1.98e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—coronary artery disease	2.97e-07	1.96e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—coronary artery disease	2.96e-07	1.95e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—coronary artery disease	2.95e-07	1.95e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK1—coronary artery disease	2.93e-07	1.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOB—coronary artery disease	2.91e-07	1.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—coronary artery disease	2.88e-07	1.91e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—coronary artery disease	2.85e-07	1.88e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—coronary artery disease	2.85e-07	1.88e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—coronary artery disease	2.83e-07	1.87e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—coronary artery disease	2.81e-07	1.86e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—coronary artery disease	2.78e-07	1.84e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—coronary artery disease	2.75e-07	1.82e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—coronary artery disease	2.74e-07	1.81e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—coronary artery disease	2.71e-07	1.79e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—coronary artery disease	2.71e-07	1.79e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—coronary artery disease	2.65e-07	1.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD36—coronary artery disease	2.64e-07	1.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—coronary artery disease	2.64e-07	1.75e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—coronary artery disease	2.63e-07	1.74e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	2.61e-07	1.72e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK1—coronary artery disease	2.6e-07	1.72e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—coronary artery disease	2.59e-07	1.71e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—coronary artery disease	2.54e-07	1.68e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—coronary artery disease	2.54e-07	1.68e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—coronary artery disease	2.5e-07	1.65e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—coronary artery disease	2.5e-07	1.65e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—coronary artery disease	2.41e-07	1.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—coronary artery disease	2.38e-07	1.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—coronary artery disease	2.34e-07	1.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—coronary artery disease	2.33e-07	1.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—coronary artery disease	2.3e-07	1.52e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—coronary artery disease	2.25e-07	1.49e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—coronary artery disease	2.25e-07	1.49e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—coronary artery disease	2.16e-07	1.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—coronary artery disease	2.08e-07	1.37e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—coronary artery disease	2.03e-07	1.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—coronary artery disease	2e-07	1.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—coronary artery disease	1.99e-07	1.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—coronary artery disease	1.84e-07	1.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—coronary artery disease	1.82e-07	1.21e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—coronary artery disease	1.82e-07	1.2e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—coronary artery disease	1.74e-07	1.15e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—coronary artery disease	1.6e-07	1.06e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—coronary artery disease	1.49e-07	9.82e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	9.82e-08	6.49e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—coronary artery disease	8.02e-08	5.3e-07	CbGpPWpGaD
